

Coronavirus Disease 2019 (COVID-19)

CDC > Coronavirus Disease 2019 (COVID-19) > Laboratories



Coronavirus Disease 2019 (COVID-19)

- Symptoms
- Testing +
- Prevent Getting Sick +
- Daily Life & Coping +
- If You Are Sick +
- People Who Need Extra Precautions +
- Frequently Asked Questions
- Travel +
- Cases, Data, & Surveillance +
- Communities, Schools & Workplaces +
- Healthcare Professionals +
- Health Departments +
- Laboratories -**
- FAQs for Laboratories
- CDC Lab Work +
- Guidelines for Clinical Specimens**
- Lab Biosafety Guidelines
- Laboratory Biosafety and COVID-19: Questions and Answers
- Requests for Diagnostic Tools and Virus
- Research Use Only Real-Time RT-PCR Primer and Probe Information
- CDC's Response +
- Global COVID-19 +
- Communication Resources +

Get Email Updates

To receive email updates about COVID-19, enter your email address:

[What's this?](#)

- ### Spanish Resources
- [Spanish Communication Resources](#)
 - [Social Media Toolkit](#)
 - [Infection Control](#)
 - [FAQ on Infection Control](#)

Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19)

[Print Page](#)

Updated April 29, 2020

Summary of Recent Changes

Revisions were made on April 29, 2020 to reflect the following:

- Update guidance on viral transport medium (VTM) to note that some point-of-care tests advise against its use.
- Removed preference for NP swabs.
- Updated guidance for use of personal protective equipment while obtaining specimens.

Revisions were made on April 14, 2020 to reflect the following:

- Clarify specimen collection procedures for all swab types and align with other respiratory disease specimen collection guidelines

Clinicians considering testing people with possible COVID-19 should work with their local and state health departments to coordinate testing through public health laboratories, or work with commercial or clinical laboratories using viral tests granted an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration. CDC has [guidance](#) for who should be tested, but decisions about testing are at the discretion of state and local health departments and/or individual clinicians. Testing for other pathogens by the provider should be done as part of the initial evaluation, as indicated, but should not delay testing for SARS-CoV-2.

Positive SARS-CoV-2 results should be reported. Read [CDC's Data and Reporting FAQ for Laboratories](#).

Clinical laboratories should NOT attempt viral isolation from specimens collected from people suspected to have COVID-19 unless this is performed in a BSL-3 laboratory.

Specimen Type and Priority

All testing for SARS-CoV-2 should be conducted in consultation with a healthcare provider. Specimens should be collected as soon as possible once a decision has been made to pursue testing, regardless of the time of symptom onset. The guidance below addresses options for collection of specimens.

For initial diagnostic testing for SARS-CoV-2, CDC recommends collecting and testing an upper respiratory specimen. The following are acceptable specimens:

- A nasopharyngeal (NP) specimen collected by a healthcare professional; or
- An oropharyngeal (OP) specimen collected by a healthcare professional; or
- An anterior nares (nasal swab) specimen collected by a healthcare professional or by onsite or home self-collection (using a flocked or spun polyester swab); or
- Nasopharyngeal wash/aspirate or nasal wash/aspirate (NW) specimen collected by a healthcare professional.

Swabs should be placed immediately into a sterile transport tube containing 2-3mL of either viral transport medium (VTM), Amies transport medium, or sterile saline, unless using a test designed to analyze a specimen directly, (i.e., without placement in VTM), such as [some point-of-care tests](#). If VTM is not available, see the standard operating procedure for public health labs to create [viral transport medium](#) in accordance with CDC's protocol.

The NW specimen and the non-bacteriostatic saline used to collect the specimen should be placed immediately into a sterile transport tube.

Testing lower respiratory tract specimens is also an option. For patients who develop a productive cough, sputum should be collected and tested for SARS-CoV-2. The induction of sputum is not recommended. When under certain clinical circumstances (e.g., those receiving invasive mechanical ventilation), a lower respiratory tract aspirate or bronchoalveolar lavage sample should be collected and tested as a lower respiratory tract specimen.

Collecting and Handling Specimens Safely

For providers collecting specimens or within 6 feet of patients suspected to be infected with SARS-CoV-2, maintain [proper infection control](#) and use recommended personal protective equipment, which includes an N95 or higher-level respirator (or facemask if a respirator is not available), eye protection, gloves, and a gown, when collecting specimens.

For providers who are handling specimens, but are not directly involved in collection (e.g. self-collection) and not working within 6 feet of the patient, follow [Standard Precautions](#); laboratory coats or gowns, gloves, and eye protection are recommended.

General Guidelines

Proper collection of specimens is the most important step in the laboratory diagnosis of infectious diseases. A specimen that is not collected correctly may lead to false negative test results. The following specimen collection guidelines follow standard recommended procedures. For more information, including illustrations and step-by-step guidance, see the [CDC Influenza Specimen Collection](#) instructions. Note that these instructions are applicable for respiratory viruses in general, and not specific for only influenza virus.

I. Respiratory Specimens

A. Upper respiratory tract

Nasopharyngeal swab/Oropharyngeal (Throat) swab

Use only synthetic fiber swabs with plastic or wire shafts. Do not use calcium alginate swabs or swabs with wooden shafts, as they may contain substances that inactivate some viruses and inhibit PCR testing. CDC is now recommending collecting only the NP swab, although OP swabs remain an acceptable specimen type. If both NP and OP swabs are collected, they should be combined in a single tube to maximize test sensitivity and limit use of testing resources.



NP swab: Insert minitip swab with a flexible shaft (wire or plastic) through the nostril parallel to the palate (not upwards) until resistance is encountered or the distance is equivalent to that from the ear to the nostril of the patient, indicating contact with the nasopharynx. Swab should reach depth equal to distance from nostrils to outer opening of the ear. Gently rub and roll the swab. Leave swab in place for several seconds to absorb secretions. Slowly remove swab while rotating it. Specimens can be collected from both sides using the same swab, but it is not necessary to collect specimens from both sides if the minitip is saturated with fluid from the first collection. If a deviated septum or blockage create difficulty in obtaining the specimen from one nostril, use the same swab to obtain the specimen from the other nostril.

OP swab: Insert swab into the posterior pharynx and tonsillar areas. Rub swab over both tonsillar pillars and posterior oropharynx and avoid touching the tongue, teeth, and gums.

Nasal mid-turbinate (NMT) swab, also called Deep Nasal Swab

Use a flocked tapered swab. Tilt patient's head back 70 degrees. While gently rotating the swab, insert swab less than one inch (about 2 cm) into nostril (until resistance is met at turbinates). Rotate the swab several times against nasal wall and repeat in other nostril using the same swab.

Anterior nares specimen

Using a flocked or spun polyester swab, insert the swab at least 1 cm (0.5 inch) inside the nostril (naris) and firmly sample the nasal membrane by rotating the swab and leaving in place for 10 to 15 seconds. Sample both nostrils with same swab.

Nasopharyngeal wash/aspirate or nasal wash/aspirate

Attach catheter to suction apparatus. Have the patient sit with head tilted slightly backward. Instill 1 mL-1.5 mL of non-bacteriostatic saline (pH 7.0) into one nostril. Insert the tubing into the nostril parallel to the palate (not upwards). Catheter should reach depth equal to distance from nostrils to outer opening of ear. Begin gentle suction/aspiration and remove catheter while rotating it gently. Place specimen in a sterile viral transport media tube.

B. Lower respiratory tract

Bronchoalveolar lavage, tracheal aspirate, pleural fluid, lung biopsy

Collect 2-3 mL into a sterile, leak-proof, screw-cap sputum collection cup or sterile dry container.

Due to the increased technical skill and equipment needs, collection of specimens other than sputum from the lower respiratory tract may be limited to patients presenting with more severe disease, including people admitted to the hospital and/or fatal cases.

Sputum

Educate the patient about the difference between sputum and oral secretions (saliva). Have the patient rinse the mouth with water and then expectorate deep cough sputum directly into a sterile, leak-proof, screw-cap collection cup or sterile dry container.

II. Storage

Store specimens at 2-8°C for up to 72 hours after collection. If a delay in testing or shipping is expected, store specimens at -70°C or below.

III. Shipping

Samples may be shipped to CDC if repeated testing results remain inconclusive or if other unusual results are obtained. Please contact CDC at respvirus@cdc.gov prior to submitting samples.

If shipping samples to CDC: If specimens will ship without delay, store specimens at 2-8°C, and ship overnight to CDC on ice pack. If a delay in shipping will result in receipt at CDC more than 72 hours after collection, store specimens at -70°C or below and ship overnight to CDC on dry ice. Additional useful and detailed information on packing, shipping, and transporting specimens can be found at [Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 \(COVID-19\)](#).

Specimens must be packaged, shipped, and transported according to the current edition of the [International Air Transport Association \(IATA\) Dangerous Goods Regulations external icon](#).

Label each specimen container with the patient's ID number (e.g., medical record number), unique CDC or state-generated nCov specimen ID (e.g., laboratory requisition number), specimen type (e.g., serum) and the date the sample was collected. Complete a [CDC Form 50.34](#) for each specimen submitted. In the upper left box of the form, 1) for *test requested* "Respiratory virus molecular detection (non-influenza) CDC-10401" and 2) for *At CDC, bring to the attention of* enter "Stephen Lindstrom: 2019-nCoV PUI."

Please refer to our instruction guidance for submitting CDC Form 50.34 found here: [Guidelines For Submitting Specimens to CDC](#).

For additional information, consultation, or the CDC shipping address, contact the CDC Emergency Operations Center (EOC) at 770-488-7100.

Page last reviewed: April 29, 2020

Content source: National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases

HAVE QUESTIONS?

- Visit CDC-INFO
- Call 800-232-4636
- Email CDC-INFO
- Open 24/7

CDC INFORMATION

- About CDC
- Jobs
- Funding
- Policies
- File Viewers & Players

Privacy

- FOIA
- No Fear Act
- OIG
- Nondiscrimination
- Accessibility

CONNECT WITH CDC



LANGUAGE ASSISTANCE

Español	Tagalog	Français	Deutsch
繁體中文	Русский	PolSKI	日本語
Tiếng Việt	العربية	Português	فارسی
한국어	Kreyòl Ayisyen	Italiano	English